Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.

Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum.

Abstract: The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

Abstract: The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Abstract: A method of treating a subject suffering from an ischemic disease associated with Ca2+ overload is provided, the method including administering to the subject an effective amount of an inhibitor of Ataxia telangiectasia and Rad3-related (ATR) kinase. Also provided is a method of treating a subject suffering from acute ischemic stroke, the method including administering to the subject an effective amount of the ATR kinase inhibitor berzosertib.

Abstract: Disclosed are PPAR receptor modulators and their uses in medicine. The novel agonists for PPAR-? were found by screening molecules through a chemoinformatics-based model. The novel agonists for PPAR-? are proposed for use in medicine.

Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.

Abstract: A disulfiram derivative of formula (I) wherein R1 and R2 are each independently an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted heteroarylalkyl, and with the proviso that R1 and R2 are not both ethyl, both benzyl, both —CH2CH2OH, or both A pharmaceutical composition containing the disulfiram derivative of formula (I), and a method of treating ALDH1a1- and/or MAGL-mediated diseases or disorders.

Abstract: A composition for treating a burn wound, containing a variety of ingredients, including a fatty acid 261-639 mg, an organic substance 3.5-350 mg, a carbohydrate 0.02-60 mg, a vitamin 9-13 ?g, a microelement 3.04-5.5 mg, an antibiotic 0.6-70 mg, and an amino acid 105-335 mg. The significant therapeutic effects include effectively promoting repair of a burn wound, anti-infection, inhibiting scar hyperplasia, no toxic side effect, convenient use, fast absorption, economical efficiency, etc. The composition provides patients with an efficient, economical, convenient and practical treatment for burn wounds, which greatly reduces the burden on patients, and effectively compensates for the various deficiencies of the current treatments for the non-healing burn wounds.

Abstract: The present invention relates to vaccine compositions for treatment of substance use disorders, methods for the manufacture thereof, and methods for the use thereof to treat an animal. These compositions comprise a hapten conjugated via a linker to a protein scaffold and mixed with a particulate carrier and at least one immunostimulatory adjuvant molecule.

Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

Abstract: The invention relates to a method of producing the radiolabeled aryl compound (I) Ar—X, or a salt thereof, wherein X is 211At, 210At, 123I, 124I, 125I, or 131I. The method involves reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide, in water.

Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

Abstract: Herein are provided novel salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylate namely the oxalate salt and the dibenzoyltartrate salt

Abstract: A BRD9 protein degrading compound of structure or a pharmaceutically acceptable salt thereof is provided for the treatment of a disorder mediated by BRD9, including but not limited to abnormal cellular proliferation including cancer.